GYRE
NASDAQGyre Therapeutics Inc.
News25/Ratings3
News · 26 weeks60+100%
2026-03-012026-08-23
Mix2790d
- Insider16(59%)
- SEC Filings9(33%)
- Leadership1(4%)
- Earnings1(4%)
Latest news
25 items- SECSEC Form 10-Q filed by Gyre Therapeutics Inc.10-Q - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- SECGyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- PRGyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business UpdateQ2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026 SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. Dr. Ying Luo, President and Chief Executive Officer of Gyre Therapeutics, commented, "I am very pleased with Gyre's progress over th
- INSIDERSEC Form 4 filed by Director Weston Claire4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Director Kirkby Maxwell4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Weston Claire3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kirkby Maxwell3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SECSEC Form EFFECT filed by Gyre Therapeutics Inc.EFFECT - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- SECGyre Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- PRGyre Therapeutics Appoints Three New Members to its Board of DirectorsSAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that its Board of Directors has appointed three new members, effective August 1, 2026: Yue Xiong, Ph.D., the Company's Chief Scientific Officer; Maxwell ("Max") Kirkby; and Claire Weston, Ph.D. With these appointments, the Board expands its scientific, clinical development, and cross-border biopharmaceutical operating expertise as Gyre advances its broad pipeline of products targeting numerous therapeutic areas including fibrosis, cancer, in
- SECAmendment: Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- SECAmendment: SEC Form S-3/A filed by Gyre Therapeutics Inc.S-3/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- INSIDERSEC Form 4 filed by Director Carmichael Gordon4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Director Weng Dan4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Director Zhang Ping4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Director Parry Renate4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Director Epstein David M.4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Director Nussbaum Rodney L4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERChief Operating Officer Ye Weiguo exercised 11,000 shares at a strike of $0.75 and sold $68,700 worth of shares (11,000 units at $6.25) (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SECGyre Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- INSIDERChief Operating Officer Ye Weiguo exercised 2,800 shares at a strike of $0.75 and sold $17,276 worth of shares (2,800 units at $6.17) (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERChief Operating Officer Ye Weiguo exercised 20,918 shares at a strike of $0.75 and sold $128,886 worth of shares (20,918 units at $6.16) (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by GC and Corporate Secretary Bergmann Joshua Benjamin4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Luo Ying4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SECSEC Form S-8 filed by Gyre Therapeutics Inc.S-8 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
GYRE FAQ
6 questionsWhere does GYRE stock trade?
Gyre Therapeutics Inc. (GYRE) is listed on NASDAQ.What sector and industry is GYRE in?
Gyre Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Gyre Therapeutics Inc. go public?
Gyre Therapeutics Inc. (GYRE) completed its IPO in 2006.What are analysts saying about GYRE?
Gyre Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1600.00 price target on 2025-10-10. Recent price targets range from $1600.00 to $1800.00.What companies are similar to GYRE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GYRE side-by-side with any of them on Quantisnow.How can I track GYRE on Quantisnow?
Quantisnow aggregates Gyre Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GYRE to receive live email and push alerts on every new disclosure.